• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

4.055 -0.175 (-4.14%)
Streaming Delayed Price Updated: 2:59 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Today 9:01 EDT
From Biotech Insider
Via GlobeNewswire
News headline image
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 03, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗
June 02, 2026
Tread carefully, but certain factors make this speculative biotech play stand out. 
Via The Motley Fool
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
June 01, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market ↗
May 07, 2026
Via Chartmill
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗
February 24, 2026
Via Chartmill
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
Via Investor Brand Network
News headline image
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
June 01, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 22, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conference
May 21, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance (IOVA) Q1 2026 Earnings Transcript ↗
May 08, 2026
Iovance (IOVA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
May 07, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street ↗
May 02, 2026
It could just as well drop by 50% -- or more -- over the next 12 months. 
Via The Motley Fool
Topics Death
News headline image
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
April 27, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? ↗
April 10, 2026
This oncology specialist has proven innovative abilities. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 20, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
March 12, 2026
Via MarketBeat
News headline image
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
March 05, 2026
If you decide to invest in this company, it's probably best to start small. 
Via The Motley Fool
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
March 05, 2026
Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases. 
Via Stocktwits
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
February 26, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
February 25, 2026
Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized. 
Via Stocktwits
Topics Earnings
Curious about the most active stocks on Tuesday? ↗
February 24, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
February 24, 2026
Via Chartmill
News headline image
Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗
February 24, 2026
Iovance (IOVA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Did IOVA Stock Gain Pre-Market Today? ↗
February 24, 2026
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings. 
Via Stocktwits
News headline image
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
February 24, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
February 24, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits ↗
February 23, 2026
The company is studying its approved drug for many other indications. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 20, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap